Bavarian Nordic Conference Call: General Monkeypox Update

·2-min read
Bavarian Nordic A/S
Bavarian Nordic A/S

COPENHAGEN, Denmark – June 3, 2022 - Bavarian Nordic A/S (OMX: BAVA) will host an investor and analyst conference call on Tuesday, June 7, 2022, at 3:00 pm CEST (9:00 am EDT) to provide a general update on the Company’s business in relation to the ongoing monkeypox outbreak.

President & CEO, Paul Chaplin and EVP and CFO, Henrik Juuel will give a presentation covering topics such as the monkeypox disease and the current outbreak, regulatory status and official recommendations on the use of the Company’s smallpox/monkeypox vaccine, and the interactions with countries and organizations worldwide on vaccine supply in both the short and long term and its impact on the Company’s business and guidance. The presentation will be followed by a Q&A session. A live and replay version of the call and relevant slides will be available at

To ask questions during the Q&A session, dial one of the following numbers and state the participant code 2765505: Denmark: +45 32 72 04 17, UK: +44 (0) 844 481 9752, USA: +1 646-741-3167

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company listed on the NASDAQ Copenhagen exchange and with operations in Europe and the USA. Our mission is to save and improve lives by unlocking the power of the immune system and we aspire to become one of the largest pure play vaccine companies by developing innovative life-saving vaccines, excelling in commercialization and being a best-in-class vaccine manufacturer. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next-generation COVID-19 vaccine and a vaccine against respiratory syncytial virus (RSV), which are both entering Phase 3 clinical trials in 2022. For more information visit

Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Tel: +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600